SCOPUS 정보 검색 플랫폼

Hypertension

Volumn 68, Issue 3, 2016, Pages 544-545

Atrial fibrillation in patients with hypertension

(1) Lip, Gregory Y H a,b

a UNIVERSITY OF BIRMINGHAM (United Kingdom)

b AALBORG UNIVERSITY (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE THERAPY; ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; HUMAN; HYPERTENSION; INCIDENCE; LONGITUDINAL STUDY; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING; SYSTOLIC BLOOD PRESSURE; RISK FACTOR;

ATRIAL FIBRILLATION; HUMANS; HYPERTENSION; RISK FACTORS;

EID: 84978066725 PISSN: 0194911X EISSN: 15244563 Source Type: Journal
DOI: 10.1161/HYPERTENSIONAHA.116.07901 Document Type: Note

Times cited : (15)

References (10)

1
- 85006802974
- Atrial fibrillation
- Lip GY, Fauchier L, Freedman SB, Van Gelder I, Natale A, Gianni C, Nattel S, Potpara T, Rienstra M, Tse HF, Lane DA, Atrial fibrillation. Nat Rev Dis Primers 2016 2 16016. doi: 10.1038/nrdp.2016.16
- (2016) Nat Rev Dis Primers , vol.2 , pp. 16016
- Lip, G.Y.¹ Fauchier, L.² Freedman, S.B.³ Van Gelder, I.⁴ Natale, A.⁵ Gianni, C.⁶ Nattel, S.⁷ Potpara, T.⁸ Rienstra, M.⁹ Tse, H.F.¹⁰ Lane, D.A.¹¹

2
- 77954177827
- Blood pressure levels and bleeding events during antithrombotic therapy: The bleeding with antithrombotic therapy (bat) study
- Bleeding with Antithrombotic Therapy (BAT) Study Group
- Toyoda K, Yasaka M, Uchiyama S, Nagao T, Gotoh J, Nagata K, Koretsune Y, Sakamoto T, Iwade K, Yamamoto M, Takahashi JC, Minematsu K, Bleeding with Antithrombotic Therapy (BAT) Study Group Blood pressure levels and bleeding events during antithrombotic therapy: the Bleeding with Antithrombotic Therapy (BAT) Study. Stroke 2010 41 1440 1444. doi: 10.1161/STROKEAHA.110.580506
- (2010) Stroke , vol.41 , pp. 1440-1444
- Toyoda, K.¹ Yasaka, M.² Uchiyama, S.³ Nagao, T.⁴ Gotoh, J.⁵ Nagata, K.⁶ Koretsune, Y.⁷ Sakamoto, T.⁸ Iwade, K.⁹ Yamamoto, M.¹⁰ Takahashi, J.C.¹¹ Minematsu, K.¹²

3
- 58149204184
- Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited
- Watson T, Shantsila E, Lip GY, Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009 373 155 166. doi: 10.1016/S0140-6736(09)60040-4
- (2009) Lancet , vol.373 , pp. 155-166
- Watson, T.¹ Shantsila, E.² Lip, G.Y.³

4
- 0033755029
- Hypertension and the prothrombotic state
- Lip GY, Hypertension and the prothrombotic state. J Hum Hypertens 2000 14 687 690
- (2000) J Hum Hypertens , vol.14 , pp. 687-690
- Lip, G.Y.¹

5
- 84978145265
- Trajectories of risk factors and risk of new-onset atrial fibrillation in the Framingham Heart Study
- Rahman F, Yin X, Larson MG, Ellinor PT, Lubitz S, Vasan RS, McManus D, Magnani JW, Benjamin EJ, Trajectories of risk factors and risk of new-onset atrial fibrillation in the Framingham Heart Study. Hypertension 2016 68 597 605. doi: 10.1161/HYPERTENSIONAHA.116.07683
- (2016) Hypertension , vol.68 , pp. 597-605
- Rahman, F.¹ Yin, X.² Larson, M.G.³ Ellinor, P.T.⁴ Lubitz, S.⁵ Vasan, R.S.⁶ McManus, D.⁷ Magnani, J.W.⁸ Benjamin, E.J.⁹

6
- 68849107251
- Repeated assessment of physical biomeasures or blood biomarkers for the definition of volume status and cardiac loading in LVSD
- Chuen MJ, Lip GY, MacFadyen RJ, Repeated assessment of physical biomeasures or blood biomarkers for the definition of volume status and cardiac loading in LVSD. Biomark Med 2007 1 355 374. doi: 10.2217/17520363.1.3.355
- (2007) Biomark Med , vol.1 , pp. 355-374
- Chuen, M.J.¹ Lip, G.Y.² MacFadyen, R.J.³

7
- 84907686452
- National-Institute-for-Health-And-Care-Excellence Accessed June 27, 2016
- National-Institute-for-Health-And-Care-Excellence Atrial fibrillation: the management of atrial fibrillation. (Clinical guideline 180.). 2014. http://guidance.Nice.Org.Uk/cg180. Accessed June 27, 2016
- (2014) Atrial Fibrillation: The Management of Atrial Fibrillation. (Clinical Guideline 180

8
- 84943138698
- Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy
- Lip GY, Skjøth F, Nielsen PB, Larsen TB, Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb Haemost 2015 114 826 834. doi: 10.1160/TH15-07-0565
- (2015) Thromb Haemost , vol.114 , pp. 826-834
- Lip, G.Y.¹ Skjøth, F.² Nielsen, P.B.³ Larsen, T.B.⁴

9
- 84970015745
- Should atrial fibrillation patients with only 1 nongender-related CHA2DS2-VASc risk factor be anticoagulated?
- In press
- Fauchier L, Clementy N, Ivanes F, Angoulvant D, Babuty D, Lip G, Should atrial fibrillation patients with only 1 nongender-related CHA2DS2-VASc risk factor be anticoagulated? Stroke. doi: 10.1161/STROKEAHA.1116.013253. In press
- Stroke
- Fauchier, L.¹ Clementy, N.² Ivanes, F.³ Angoulvant, D.⁴ Babuty, D.⁵ Lip, G.⁶

10
- 84988529625
- Bleeding risk assessment in atrial fibrillation: Observations on the use and misuse of bleeding risk scores
- In press
- Lip GY, Lane DA, Bleeding risk assessment in atrial fibrillation: Observations on the use and misuse of bleeding risk scores. J Thromb Haemost. doi: 10.1111/jth.13386. In press
- J Thromb Haemost
- Lip, G.Y.¹ Lane, D.A.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.